Findings from the phase 3 randomized CABASTY clinical trial “may be practice changing,” investigators reported. Biweekly vs triweekly cabazitaxel for mCRPC in men aged 65 years or older has similar efficacy but is associated with a lower risk for neutropenia and/or neutropenic complications.